[Iron metabolism and chloroquine phosphate therapy in porphyria cutanea tarda].
The knowledge about the influence of chloroquine phosphate (CQ) on the iron metabolism in porphyria cutanea tarda (PCT) is still insufficient. In a study on 138 PCT patients treated with CQ, we observed decreasing serum iron concentration, transferrin saturation, and hepatic siderosis, as well as an increasing level of transferrin. After a one-year therapy with CQ, the patients showed normal porphyrinuria. Since there were no statistical correlations between the degree of hepatic siderosis and porphyrinuria, and since we repeatedly found remission of the PCT in spite of the continued existence of hepatic siderosis, the removal of iron cannot be regarded as the only principle of action in CQ therapy. In comparison with chloroquine, phlebotomy obviously has--even with regard to the iron deposits--no decisive advantages.
Köstler
E
E
Hautklinik des Bezirkskrankenhauses Dresden-Friedrichstadt.
Pollack
P
P
Seebacher
C
C
Riedel
H
H
D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal; D002738:Chloroquine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007501:Iron / Q000097:blood*; D008297:Male; D011164:Porphyrias / Q000097:blood / Q000188:drug therapy*; D011166:Porphyrins / Q000652:urine; D012871:Skin Diseases / Q000097:blood / Q000188:drug therapy*; D014168:Transferrin / Q000378:metabolism
D000894:Anti-Inflammatory Agents, Non-Steroidal; D011166:Porphyrins; D014168:Transferrin; C023676:chloroquine diphosphate; D002738:Chloroquine; D007501:Iron
Eisenstoffwechsel und Chloroquinphosphattherapie der Porphyria cutanea tarda.